MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy

被引:1
作者
Arnoff, Taylor E. [1 ]
El-Deiry, Wafik S. [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Brown Univ, Warren Alpert Med Sch, Lab Translat Oncol & Expt Canc Therapeut, Providence, RI 02912 USA
[2] Brown Univ, Dept Med, Lifespan Hlth Syst, Hematol Oncol Div, Providence, RI 02912 USA
[3] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[4] Brown Univ, Lifespan Hlth Syst, Joint Program Canc Biol, Providence, RI 02912 USA
[5] Brown Univ, Warren Alpert Med Sch, Legorreta Canc Ctr, Providence, RI 02912 USA
[6] Brown Univ, Lifespan Hlth Syst, Dept Pathol & Lab Med, Providence, RI 02912 USA
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2022年 / 12卷 / 05期
关键词
MDM2; MDM4; melanoma; GBM; CDKN2A; cancer therapy; immunotherapy; CLINICAL-OUTCOMES; BLOCKADE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic melanoma has a five-year survival of similar to 10%, with a paucity of biomarkers predicting metastasis to specific anatomic sites or targeted therapies for metastases. We analyzed 1015 primary and 358 metastatic melanomas and found metastatic disease is enriched for MDM2 and MDM4 amplifications compared to primary disease, and amplifications are associated with lower overall survival. MDM2/4 amplifications are associated with a higher rate of metastasis to the brain and liver. Two negative regulators of p53, USP7 and PPM1D, are also altered in metastatic melanoma compared to primary disease. These findings suggest that patients with metastatic melanoma have a dysregulated TP53 pathway compared to primary disease. We propose that patients with metastatic melanoma and wild-type TP53 may be more likely to benefit from MDM2, MDM4, USP7, and PPM1D inhibitors. Patients with MDM2/4 amplification display deep deletions in CDKN2A, alterations also associated with a higher rate of metastasis to the brain. Patients with a CDKN2A deletion have a higher rate of alterations in TTN, MUC16, LRP1B, and NF1, alterations previously associated with favorable response to immune-checkpoint inhibitors in melanoma. We propose CDKN2A alteration as a potential biomarker to predict response to immunotherapy in melanoma. We found that GBM displays the highest rate of MDM4 amplifications (9.63%) and CDKN2A deletions (54.39%) across all cancer types. In 592 GBM samples we found that 8.45% display MDM2 amplification. We suggest that patients with melanoma or GBM and amplifications in MDM2/4 and CDKN2A alterations may benefit from combinations of targeted inhibitors of MDM2/4 and CDK4/6, as well as immunotherapy.
引用
收藏
页码:2102 / 2117
页数:16
相关论文
共 29 条
[1]   Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution [J].
Abbosh, Christopher ;
Birkbak, Nicolai J. ;
Wilson, Gareth A. ;
Jamal-Hanjani, Mariam ;
Constantin, Tudor ;
Salari, Raheleh ;
Le Quesne, John ;
Moore, David A. ;
Veeriah, Selvaraju ;
Rosenthal, Rachel ;
Marafioti, Teresa ;
Kirkizlar, Eser ;
Watkins, Thomas B. K. ;
McGranahan, Nicholas ;
Ward, Sophia ;
Martinson, Luke ;
Riley, Joan ;
Fraioli, Francesco ;
Al Bakir, Maise ;
Gronroos, Eva ;
Zambrana, Francisco ;
Endozo, Raymondo ;
Bi, Wenya Linda ;
Fennessy, Fiona M. ;
Sponer, Nicole ;
Johnson, Diana ;
Laycock, Joanne ;
Shafi, Seema ;
Czyzewska-Khan, Justyna ;
Rowan, Andrew ;
Chambers, Tim ;
Matthews, Nik ;
Turajlic, Samra ;
Hiley, Crispin ;
Lee, Siow Ming ;
Forster, Martin D. ;
Ahmad, Tanya ;
Falzon, Mary ;
Borg, Elaine ;
Lawrence, David ;
Hayward, Martin ;
Kolvekar, Shyam ;
Panagiotopoulos, Nikolaos ;
Janes, Sam M. ;
Thakrar, Ricky ;
Ahmed, Asia ;
Blackhall, Fiona ;
Summers, Yvonne ;
Hafez, Dina ;
Naik, Ashwini .
NATURE, 2017, 545 (7655) :446-+
[2]   Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy [J].
Ahmed, K. A. ;
Stallworth, D. G. ;
Kim, Y. ;
Johnstone, P. A. S. ;
Harrison, L. B. ;
Caudell, J. J. ;
Yu, H. H. M. ;
Etame, A. B. ;
Weber, J. S. ;
Gibney, G. T. .
ANNALS OF ONCOLOGY, 2016, 27 (03) :434-441
[3]   LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types [J].
Brown, Landon C. ;
Tucker, Matthew D. ;
Sedhom, Ramy ;
Schwartz, Eric B. ;
Zhu, Jason ;
Kao, Chester ;
Labriola, Matthew K. ;
Gupta, Rajan T. ;
Marin, Daniele ;
Wu, Yuan ;
Gupta, Santosh ;
Zhang, Tian ;
Harrison, Michael R. ;
George, Daniel J. ;
Alva, Ajjai ;
Antonarakis, Emmanuel S. ;
Armstrong, Andrew J. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
[4]   PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma [J].
Catalanotti, Federica ;
Cheng, Donavan T. ;
Shoushtari, Alexander N. ;
Johnson, Douglas B. ;
Panageas, Katherine S. ;
Momtaz, Parisa ;
Higham, Catherine ;
Won, Helen H. ;
Harding, James J. ;
Merghoub, Taha ;
Rosen, Neal ;
Sosman, Jeffrey A. ;
Berger, Michael F. ;
Chapman, Paul B. ;
Solit, David B. .
JCO PRECISION ONCOLOGY, 2017, 1 :1-15
[5]   Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history [J].
Chan, Andrew K. ;
Han, Seunggu J. ;
Choy, Winward ;
Beleford, Daniah ;
Aghi, Manish K. ;
Berger, Mitchel S. ;
Shieh, Joseph T. ;
Bollen, Andrew W. ;
Perry, Arie ;
Phillips, Joanna J. ;
Butowski, Nicholas ;
Solomon, David A. .
CLINICAL NEUROPATHOLOGY, 2017, 36 (05) :213-221
[6]   The genetics of malignant melanoma: Lessons from mouse and man [J].
Chin, L .
NATURE REVIEWS CANCER, 2003, 3 (08) :559-570
[7]   Association of melanoma with glioblastoma multiforme [J].
Desai, A. S. ;
Grossman, S. A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[8]   Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States [J].
Donley, Grayson M. ;
Liu, Wayne T. ;
Pfeiffer, Ruth M. ;
McDonald, Emily C. ;
Peters, Kamau O. ;
Tucker, Margaret A. ;
Cahoon, Elizabeth K. .
BRITISH JOURNAL OF CANCER, 2019, 120 (07) :754-760
[9]  
Heistein J., 2022, Malignant Melanoma,
[10]   Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma [J].
Hugo, Willy ;
Zaretsky, Jesse M. ;
Sun, Lu ;
Song, Chunying ;
Moreno, Blanca Homet ;
Hu-Lieskovan, Siwen ;
Berent-Maoz, Beata ;
Pang, Jia ;
Chmielowski, Bartosz ;
Cherry, Grace ;
Seja, Elizabeth ;
Lomeli, Shirley ;
Kong, Xiangju ;
Kelley, Mark C. ;
Sosman, Jeffrey A. ;
Johnson, Douglas B. ;
Ribas, Antoni ;
Lo, Roger S. .
CELL, 2016, 165 (01) :35-44